HUTCHMED (China) (HCM) Total Non-Current Liabilities (2015 - 2026)
HUTCHMED (China) (HCM) posted quarterly Total Non-Current Liabilities of $363.6 million for Q2 2026, up 6072.78% year-over-year from $5.9 million in Q2 2025, and up 608.46% quarter-over-quarter from $51.3 million in Q4 2025.
HUTCHMED (China) (HCM) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HCM) has reported Total Non-Current Liabilities for 12 consecutive years, with $363.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Non-Current Liabilities rose 6072.78% year-over-year to $363.6 million; the TTM figure through Jun 2026 stood at $363.6 million (up 6072.78% YoY), while the FY2025 annual figure was $5.0 million, up 28.69% from the prior year.
- Total Non-Current Liabilities rose to $363.6 million in Q2 2026 per HCM's latest filing, from $51.3 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $478.2 million in Q2 2023 and bottomed at -$2.8 billion in Q4 2023.
- Historically, Total Non-Current Liabilities has averaged -$202.6 million across 5 years, with a median of $47.0 million in 2022.
- On a YoY basis, Total Non-Current Liabilities climbed as much as 7835.38% in 2023 and fell as far as 6148.6% in 2023.
- HUTCHMED (China)'s Total Non-Current Liabilities stood at $47.0 million in 2022, then tumbled by 6148.6% to -$2.8 billion in 2023, then soared by 102.17% to $61.7 million in 2024, then dropped by 16.87% to $51.3 million in 2025, then soared by 608.46% to $363.6 million in 2026.
- Business Quant data shows HCM's Total Non-Current Liabilities at $363.6 million in Q2 2026, $51.3 million in Q4 2025, and $5.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | HUTCHMED (China) | 2.18 Bn | 2.18 Bn | - | 363.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 363.58 Mn |
| Dec 31, 2025 | 51.32 Mn |
| Jun 30, 2025 | 5.89 Mn |
| Dec 31, 2024 | 61.74 Mn |
| Jun 30, 2024 | 4.03 Mn |
| Dec 31, 2023 | -2.84 Bn |
| Jun 30, 2023 | 478.19 Mn |
| Dec 31, 2022 | 46.96 Mn |
| Jun 30, 2022 | 6.03 Mn |
| Dec 31, 2021 | 35.81 Mn |
| Jun 30, 2021 | 28.67 Mn |
| Mar 31, 2021 | 221.92 Mn |
| Dec 31, 2020 | 16.03 Mn |
| Jun 30, 2020 | -37.62 Mn |
| Dec 31, 2019 | 48.69 Mn |
| Sep 30, 2019 | 108.85 Mn |
| Jun 30, 2019 | 114.32 Mn |
| Mar 31, 2019 | 130.61 Mn |
| Dec 31, 2018 | 117.46 Mn |
| Jun 30, 2018 | 117.25 Mn |